Metronidazole Article Summary: Bacterial vaginosis is a major cause of vaginal infections during pregnancy and accounts for 40% of these cases. Generally, bacterial vaginosis is associated with several obstetric complications such as preterm labor and delivery, premature rupture of membranes, postpartum endometrisis and chorioamnionitis (Wang et. al., 2010, p.444). Metronidazole has traditionally been used as the drug of choice in the treatment of bacterial vaginosis because it is an agent of the nitroimidazole family of antibiotics. This drug has been used for several decades because its efficiency in treating the condition varies between 80 and 90% and it can be administered in all stages of pregnancy while being tolerated by pregnant women. The drug's ability to achieve high levels of efficacy is attributed to the fact that it can be found in cord blood, fetal tissue and amniotic fluid in high concentrations. The authors of the article reported the results of two initial studies conducted on the administration of the drug to pregnant women diagnosed with bacterial vaginosis. One of the studies was conducted during pregnancy after a single intravenous administration of the drug, while the other was performed after administration of single or multiple oral doses between the eighth and fourteenth week of pregnancy. Both studies demonstrated that the pharmacokinetic stenosis of the drug in pregnant women is similar to that of healthy volunteers. Analyzes also demonstrated that after nearly 34 weeks of gestation, pregnancy-induced increases in plasma volume, which could impact the distribution of metronidazole, reach their maximum. In light of the results of the study, the pharmacokinetic parameters of this drug would be v. ..... half of the document ...... found in any patient with the disease and provides special information associated with the staging or anatomical extent of the disease. The other attribute that makes the antigen an ideal tumor cell producer includes the fact that it allows for early identification of treatment failure resulting in early salvage treatment. Prostate-specific antigen is sensitive in determining persistent or recurrent disease after treatment and has had a significant effect on every aspect of prostate cancer patient care. The effectiveness of the antigen as an ideal tumor cell producer is evident in the fact that there is currently no better technique than prostate specific antigen for evaluating prostate cancer patients after treatment. Prostate-specific antigen is the ideal producer of tumor cells despite its limitations and is commonly used for cancer screening in the general population (“Tumor Makers”, 2013).